Compare Neurocrine Biosciences Inc (NBIX) vs S&P500 ETF (SPY) Price & Performance

Neurocrine Biosciences IncTrade

S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs S&P500 ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while S&P500 ETF trades at $747.89. Which is the better fit depends on your goals.

	NBIX	SPY
Market Cap	$17.40B	—
Sector	Health	—
52-Week High	$180.55	$759.55
52-Week Low	$123.10	$621.75
Enterprise Value	$16.49B	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 7 hours agoBullish View details →

SPY

Vanguard's VEA ETF offers low-cost developed market exposure beyond the U.S., balancing diversification and risk.24/7 Wall Street · 9 hours agoNeutral John Hancock Financial Opportunities Fund offers 6.5% growing dividend, beating S&P 500 and financial ETFs.Forbes · 16 hours agoBullish XLK ETF hides high concentration risk in top tech stocks despite low fees.24/7 Wall Street · 1 day agoNeutral View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.